ERA-NET TRANSCAN-3: Next generation cancer immunotherapy: targeting the tumour microenvironment

This call of TRANSCAN focuses on:  “"Next generation cancer immunotherapy: targeting the tumour microenvironment"”

The call has three specific aims, and proposals must cover at least one of the specific topics listed below:

Aim 1: Identification and validation of TME subclasses and their contribution to the resistance mechanisms

Aim 2: Identification and validation of TME subclasses and their contribution to the resistance mechanisms

Each research consortium must involve a minimum of three (3) and a maximum of six (6) partners, eligible for funding, coming from different countries whose funders participate in the call.

Israeli applicants should contact Chief Scientist of the Minsitry of Health (Dr. Irit Alon/ Dr. Ayelet Zamir) to review and approve submission prior to application. 

Pls. note that in most cases applicants may hold only one MOH grant at any given time. Please check eligibility.

MOH will award  2 grants. 

Funding: €140,000 total for Israeli partner + €20,000 for coordination
Duration: 3 years

Research Authority due date: 22.6.21

Pre proposal due date: 29.6.21
Full proposal due date:  20.12.21